This realization comes from a convergence of information which includes understanding that there is a metabolic component to PD pathophysiology; promising clinical trials on GLP-1R agonists in PD and the realization that MPC is a novel target of new insulin sensitizers that can be targeted with clinically safe drugs that show promising effects in laboratory models of PD. Here, GLP1R is linked to Parkinson disease.